CS First Boston Upgrades Praecis Pharmaceutical

Analyst Meirov Chevav says the sharp decline in price following the FDA's response on its Plenaxis drug creates a buying opportunity

CS First Boston upgraded Praecis Pharmaceutical (PRCS ) to strong buy from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.